Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01710813 · ClinicalTrials.gov registry record
Alglucosidase Alfa Pompe Safety Sub-Registry
A clinical trial, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- 110
- Enrollment target
NCT01710813 is a clinical trial that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 110 participants.
The verdict
NCT01710813 has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
Study Summary
To collect uniform and meaningful data on patients with Pompe disease who experience anaphylaxis, severe allergic reactions, and/or signals of severe cutaneous and/or systemic immune complex-mediated reactions following treatment with alglucosidase alfa.
Interventions
- BIOLOGICAL alglucosidase alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2015-03-20 |
| Est. Completion | 2021-04-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01710813
The ClinicalTrials.gov registry entry for NCT01710813 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which alglucosidase alfa is the first listed.
NCT01710813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01710813 about?
NCT01710813 is a clinical study titled "Alglucosidase Alfa Pompe Safety Sub-Registry". To collect uniform and meaningful data on patients with Pompe disease who experience anaphylaxis, severe allergic reactions, and/or signals of severe cutaneous and/or systemic immune complex-mediated reactions following treatment with alglucosidase alfa.
What is the current status of trial NCT01710813?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2015-03-20. Estimated completion is 2021-04-20.
What interventions are being tested in trial NCT01710813?
The interventions under investigation include: alglucosidase alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT01710813?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.